Chrysophanol Exerts Anti-inflammatory Activity by Targeting Histone Deacetylase 3 Through the High Mobility Group Protein 1-Nuclear Transcription Factor-Kappa B Signaling Pathway in vivo and in vitro

Chrysophanol (Chr) is the main monomer isolated from Rheum rhabarbarum. This study aimed to identify the potential in vitro and in vivo cytoprotective effects of Chr on lipopolysaccharide (LPS)-triggered acute lung injury (ALI). We used an ALI-murine model and constructed an inflammatory macrophage in vitro cell model to determine the cellular mechanisms involved in Chr-mediated activity. To observe the vital role of histone deacetylase 3 (HDAC3) in abolishing inflammation action, HDAC3 was downregulated using small interfering RNA. Analysis of the expression of nuclear transcription factor-kappa B p65 (NF-κB p65) and molecules of its downstream signaling pathway were assessed in vitro and in lung tissue samples using the mouse model. Concentrations of tumor necrosis factor-α, interleukin-1β, high mobility group protein 1 (HMGB1), and interleukin-16 in supernatants and the bronchoalveolar lavage fluid were measured using enzyme-linked immunosorbent assay. A reporter gene assay measured HMGB1 activity, and NF-κB p65 and HMGB1 intracellular localization was determined by immunofluorescence detection on histological lung samples from Chr-treated mice. The protein interactions between HMGB1, HDAC3, and NF-κB p65 were tested by co-immunoprecipitation. Chr treatment relieved LPS-induced lung lesions. Chr also enhanced superoxide dismutase levels in ALI mice. Chr reduced the LPS-induced protein expression of NF-κB and its related pathway molecules in both in vivo and in vitro models. Moreover, Chr downregulated LPS-enhanced HMGB1 expression, acetylation, and nuclear nucleocytoplasmic translocation. However, HDAC3 knockdown substantially reduced Chr-mediated HDAC3/NF-κB expression. Furthermore, Chr enhanced HMGB1/HDAC3/NF-κB p65 complex interaction, whereas HDAC3 knockdown reduced Chr-mediated HMGB1/HDAC3/NF-κB p65 formation. This study showed that the protective effects induced by Chr were associated with the regulation of the HMGB1/NF-κB pathway via HDAC3.


INTRODUCTION
Sepsis, a generalized inflammatory state induced by lipopolysaccharide (LPS) infection, usually leads to acute lung injury (ALI). Sepsis can induce multi-organ dysfunction syndrome or septic shock (Drewry et al., 2017). Septic ALI is induced by a lung inflammatory response syndrome, which leads to high mortality rates, high patient management costs, and accelerated morbidity (Ishii, 2011). LPS is the main component of the outer membrane of Gram-negative bacteria and induces lung leukocyte activation and promotes the secretion of inflammatory cytokines. Effective treatment for sepsis shock for ALI remains limited, and it is necessary to find novel agents.
As a late pro-inflammatory factor, the extracellular high mobility group box 1 (HMGB1) protein triggers responses that cause damage to tissues leading to the activation of the inflammatory cascade in several conditions, including lung injury and septic shock (Czura et al., 2004;El Gazzar, 2007). LPS diffuses into the lung via blood circulation, activates macrophages, and promotes HMGB1 release. Extracellular HMGB1 recognizes and binds to its receptors, for example, Toll-like receptor 4, and may activate NF-κB by its translocation to the nucleus where it triggers the transcription and release of inflammatory mediators, including tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, and IL-6 ( Valdes-Ferrer et al., 2015). Therefore, HMGB1/NF-κB activation and nucleocytoplasmic transport might show promise as a crucial pathway in the development of ALI.
A crucial epigenetic factor present in macrophages is a histone deacetylase (HDAC). Its activation is triggered by transient inflammatory stimuli and results in the increased synthesis and release of pro-inflammatory cytokines in numerous diseases, including septic shock and ALI. In the latter, attenuation of HDAC activity has been reported to decrease the expression of inflammatory cytokines (Leoni et al., 2002;Pooladanda et al., 2019). Moreover, histone deacetylase 3 (HDAC3) has been reported to promote hyperacetylation and translocation of HMGB1, suggesting a pivotal role for HDACs in regulating the HMGB1 translocation (Zou and Crews, 2014;Banerjee et al., 2015;Pooladanda et al., 2019). Conversely, inhibition of HDAC3 decreased TNF-α levels and was accompanied by a co-dependent increase in acetylated p65, a subunit of NF-κB, which has been reported to play a vital role in abolishing IκBα-mediated NF-κB transcriptional activity (Kiernan et al., 2003;Zhu et al., 2010).
Rhubarb (Rheum rhabarbarum) is a well-known traditional medicinal herb that has been widely used in clinical and pharmacological studies. Chrysophanol (Chr), a bioactive compound isolated from Rhubarb, has been reported to protect the human body from LPS-induced toxicity (Kim et al., 2010;Menghini et al., 2016). In the treatment of lung diseases, Chr can reverse lung injury via its antiinflammatory and immunosuppressive effects (Qian et al., 2011;Lian et al., 2017). Our previous studies have reported that Chr inhibited the LPS-triggered release of proinflammatory factors, downregulating NF-κB gene expression and activation via regulation of the PPARγ pathway (Wen et al., 2018); however, the detailed molecular mechanisms involved in Chr-mediated effects on the NF-κB pathway are still elusive.
Hence, we propose that Chr attenuates macrophage activation, reduces levels of intrapulmonary inflammation-associated cytokines, and improves LPS-induced sepsis shock through the HMGB1/NF-κB axis by regulating HDAC3.

Experimental Animals and Protocols
Male BALB/c mice (18-22 g) were supplied and housed in the laboratory animal services center (Guangzhou University of Chinese Medicine, Guangzhou, China). The animals were housed in specific pathogen-free surroundings, provided with food and sterilized water ad libitum, and exposed to 12 h light/dark cycles and appropriate temperature and humidity. All experimental methods were followed in accordance with the Institutional and National Institutes of Health guidelines for humane animal experimentation. Animal handling followed the dictates of the National Animal Welfare Law of China.

Measurement of Blood Pressure and Mortality
Sodium pentobarbital (30 mg/kg) was used to anesthetize mice by intraperitoneal injection. To monitor blood pressure and drug administration, the neck skin was dissected to expose and cannulate the right carotid artery and connected to a blood pressure transducer (BL-420 Apparatus). The mice were grouped into the control group (isotonic saline, n = 12) and the LPS-treated group (15 mg/kg, n = 72). After LPS treatment, mice went into shock (30 min later, blood pressure reduced by ∼30%); we divided the 72 shock-induced mice into six groups: six groups received increasing does of Chr (7.5, 15, and 30 mg/kg) (Kim et al., 2010;Lian et al., 2017), the DEX treatment group (2 mg/kg) and the LPS group (LPS only). Every 30 min, the blood pressure [mean arterial pressure (MAP)] was recorded for 5 h. The survival rate was tested at the 24 h time point to assess the efficacy of Chr treatment.

Tissue Extraction
Mice (n = 12 per group) were killed after 24 h, the right lung tissues were rapidly collected under aseptic conditions, and after washing, approximately 50% of the total lung tissue was transferred to −80 • C for subsequent quantitative realtime polymerase chain reaction or Western blotting (WB), and another portion of the tissue was fixed in 10% formalin for histological studies.

Histological Analysis
The fixed left lungs were rendered transparent for 20 h, embedded in paraffin wax, and sliced into 4 µm sections. After staining, the morphological structure and pathological index of the lung tissues were determined under a light microscope. The lung inflammation was scored by its histological severity as follows: grade 0: no inflammatory cells, grade (1) few cells, grade (2) a ring of cells surrounding the vessels with infiltration 1 cell layer deep, (3) a ring of cells 2-4 cell layers deep; and (4) a ring of cells with more than 4 cell layers deep.

Evaluation of Lung Wet-to-Dry Ratio
After blunt dissection, the right lung trachea and esophagus were exposed from the right middle lobe, and the level of pulmonary edema was determined. Next, samples were placed in an oven at 60 • C for 48 h and allowed to dry by eliminating moisture, then wet-to-dry (W/D) ratios were calculated.

Collection of Bronchoalveolar Lavage Fluid
After treatment with Chr, lung tissue samples were collected and infused three times in phosphate-buffered saline. Bronchoalveolar lavage fluid (BALF) fluid was collected, centrifuged, and then stored at −80 • C for subsequent analyses.

Biochemical Tests
The activities of MPO, SOD, and MDA in the BALF samples from the mouse model were detected following the manufacturer's instructions using a commercial detection product (Jiancheng Bioengineering).

MTT Assay
The MTT assay detected cell activity. First, RAW264.7 cells (5 × 10 3 cells/ml) were seeded in a 96-well plate overnight. The cells were treated with increasing concentrations of Chr (5, 10, 15, and 20 µM) for an additional 24 h. Next, MTT was added for the final 4 h of culture at 37 • C away from light, and the absorbance values were detected at 480 nm.

Transient Transfection and Luciferase
Reporter Assays RAW264.7 cells were seeded in 24-well plates for 12 h. HMGB1 promoter-reporter plasmids and corresponding negative control (NC) vectors were transiently transfected into cells using Lipofectamine 2000 (Invitrogen, United States). Transfected cells were treated with LPS and/or Chr for another 24 h. Luminescence was determined by the Dual-Luciferase Reporter Assay System (Promega). The ratio of Firefly luciferase/Renilla luciferase was used to normalize the luminescence intensity.

Total RNA Extraction and Quantitative
Real-Time Polymerase Chain Reaction RAW264.7 cells or lung tissue samples were lysed by TRIzol reagent (Invitrogen). For qRT-PCR, the reaction steps were performed according to the protocol indicated by the manufacturer (Fermentas, United States). Thermal cycling conditions were 9 s at 95 • C, 5 s at 95 • C, followed by 40 cycles at 95 • C for 13 s, 60 • C for 1 min, and 95 • C for 17 s in a StepOnePlus thermocycler (Applied Biosystems). The primer sequences are listed in Table 1.
Cytokine Assay by Enzyme-Linked Immunosorbent Assay ELISA kits were used to measure the levels of inflammatory factors (TNF-α, IL-6, IL-1β, and HMGB1) in supernatant or tissues in accordance with the manufacturer's protocols. The emission absorbance of 480 nm was detected using a Thermomax microplate reader.

Preparation of Protein Extracts and Western Blotting
Briefly, cells were washed, lysed, and centrifuged. Next, cytoplasmic protein extracts were obtained, and the pellets containing nuclei were resuspended, placed on ice for 20 min, and the nuclear debris was centrifuged at 15,000×g for 15 min. Cells were lysed in mammalian protein extraction reagent (Thermo Fisher Scientific, Pierce). Total proteins and nuclear and cytoplasmic fractions were collected. The protein concentrations were analyzed using the bicinchoninic acid protein assay kit (Thermo Fisher Scientific, Pierce) and were stored at −80 • C until use. The lung tissues were quickly lysed using ice-cold radioimmunoprecipitation assay lysis buffer.

Small Interfering RNA Transfection
HDAC3 small interfering RNA (siRNA) and the non-specific NC were constructed by GenePharma (Shanghai, China). The transient siRNA transfection was performed by the protocol indicated by the manufacturer. Cells were transfected for 24 h and then treated with 0.2 µg/ml LPS for 30 min; after that, cells were treated with increasing concentrations of Chr (5, 10, 15, and 20 µM) for 24 h. At the end of the treatment period, we collected cells for WB and immunofluorescence analysis.

Co-immunoprecipitation
Protein immunoprecipitation (IP) was carried out with antibodies against HMGB1, HDAC3, and NF-κB (CST). Immunoglobulin G was used as a parallel-group. First, samples were incubated with immunoglobulin G reagent to be precleared. Samples were then treated with anti-HMGB1 (1:500), HDAC3 (1:500), and NF-κB (1:500) antibodies; 24 h later, lysates were incubated with protein A/G-agarose for another 2 h. Finally, samples were washed three times in phosphate-buffered saline and subjected to WB analysis.

Statistical Analysis
GraphPad Prism version 6.0 (GraphPad Software, La Jolla, CA, United States) was used to evaluate the data. Multiple comparisons between the groups were performed using one-way analysis of variance, followed by variance with Tukey's test. A value of P < 0.05 was considered statistically significant; data are expressed as the means ± SD.

RESULTS
Chrysophanol Treatment Improved the Pathological Changes in Lung Tissues, Survival Rates, and Mean Arterial Pressure of Mice With Lipopolysaccharide-Induced Shock We used hematoxylin-eosin staining to reveal the pathological changes on pulmonary tissue. Compared with the control group, the LPS group presented distinct neutrophil sequestration and infiltration in the lung tissue. The Chr-and DEX-treated groups showed varying degrees of protective effects in the LPS-induced mouse model (Figures 1A,B).
As an essential indicator of the therapeutic outcome of Chr, the survival rate of mice was measured ( Figure 1C). Administration of 15 mg/kg LPS led to 70% mice mortality (P < 0.001). Chr treatment (Chr 30 mg/kg) protected mice from LPS-induced lethality, as shown by the higher survival rates; in addition, survival rates were better than those of the DEX group. Next, we evaluated the impact of Chr on MAP in our mouse model. LPS administration lowered the MAP by > 30% (P < 0.01). In contrast, Chr significantly restored the reduction in MAP in ALI mice, more strongly than with DEX treatment ( Figure 1D).
Effects of Chrysophanol on Wet-to-Dry, Myeloperoxidase in Lung Tissues, Malondialdehyde, and Superoxide Dismutase Activities in Bronchoalveolar Lavage Fluid To estimate the degree of pulmonary edema, the W/D weight ratio, MDA, and SOD levels in BALF were calculated.
Chr notably decreased the LPS-induced lung W/D weight ratio (Figure 2A). LPS sharply increased the production of MPO and MDA, whereas Chr treatment (7.5, 10, and 20 mg/kg) remarkably decreased MPO and MDA levels in the BALF (Figures 2B,D). The SOD index was downregulated in the LPSinduced sepsis model group, and Chr (7.5, 10, and 20 mg/kg) treatment led to a significant increase in SOD activity in BALF ( Figure 2C).

Chrysophanol Inhibited High Mobility
Group Protein 1/Nuclear Transcription Factor-Kappa B p65 Signaling Pathway Activity in the Acute Lung Injury Model As shown in Figures 3A,B, we explored the inflammatory response in murine lung tissue. We detected NF-κB pathwayrelated proteins using WB analysis. The expression of NF-κBp65, p-NF-κB p65, IκBα, p-IκBα, HMGB1, TNF-α, and IL-1β increased in the LPS-treated group. As anticipated, Chr (7.5 and 15 mg/kg) or DEX treatment significantly inhibited the expression of these proteins. The results indicated that Chr possessed the anti-inflammatory activity in treating LPSinduced ALI through the HMGB1/NF-κB pathway. Moreover, we also found that Chr significantly downregulated LPS-induced HDAC3 protein levels. The ELISA result confirmed that the LPS group presented significantly enhanced TNF-α, IL-6, IL-1β, and HMGB1 release in BALF; however, their concentrations were decreased after Chr treatment (Figures 3C-F). These data indicated that Chr could sharply inhibit the levels of inflammatory factors in the ALI mouse model.

Chrysophanol Reduced Lipopolysaccharide-Induced High Mobility Group Protein 1 Expression, Nucleocytoplasmic Translocation, and Acetylation in Macrophages
Our previous study found Chr could attenuate inflammatory factor levels in LPS-induced macrophages. To investigate the potential role of Chr, we examined the effects of Chr on HMGB1 in vitro. We evaluated HMGB1 promoter activity and mRNA levels. Treatment with Chr (5, 10, and 15 µM) and the HMGB1 inhibitor SB (10 µM) significantly inhibited LPSinduced HMGB1 promoter activity ( Figure 5A) and mRNA expression (Figure 5B), compared with the LPS-treatment group. We also evaluated the influence of Chr on total, cytoplasmic, and nuclear HMGB1 protein levels by WB. As shown in Figures 5C-E, total and cytoplasmic HMGB1 levels increased, whereas the nuclear levels decreased after LPS stimulation. However, all these effects were reversed by exposure to Chr.
Immunofluorescent assay results also supported our conclusion. Nuclear-cytoplasmic translocation of HMGB1 was induced by LPS (Figure 5G, middle). Simultaneous treatment with Chr reduced cytoplasmic HMGB1 and enhanced nuclear localization of HMGB1 (Figure 5G, right), similar to unstimulated cells (Figure 5G, left), which provided morphological evidence to support our results.
To explore whether the HMGB1 translocation is related to its deacetylation, we analyzed the content of acetylated HMGB1 by IP ( Figure 5H). When LPS-induced RAW264.7 cells to release HMGB1, we found acetylated HMGB1 levels were enhanced. Conversely, HMGB1 acetylation was markedly decreased after Chr treatment, indicating that Chr interfered with the acetylation of HMGB1 (Figure 5H).

Effects of Chrysophanol on Nuclear Transcription Factor-Kappa B Pathway After Histone Deacetylase 3 Knockdown
Our previous study demonstrated that Chr significantly reduced LPS-activated NF-κB promoter and the expression of mRNA, protein, and phosphorylation of components of the NF-κB pathway (Wen et al., 2018). Because Chr significantly downregulated HDAC3 protein expression and inhibited NF-κB pathway activation in the sepsis shock mice model, we then performed in vitro model experiments to clarify the potential mechanisms involved. To specifically knockdown HDAC3 levels, we used targeted siRNA inhibition. After LPS induction, Chr (15 µM) and HDAC3 antagonist RGFP966 (10 µM) were added to cells for 24 h. Then, qPCR and WB were performed. As shown in Figures 6A-E, mRNA and protein expression (NF-kB p65, IκBα, IL-1β, and TNFα) in the control group and siNC group were unchanged. Instead, after siHDAC3 transfection, the mRNA and protein levels of NF-kB p65, IκBα, IL-1β, and TNFα were more remarkably downregulated than the control group (P < 0.01). After transfected HDAC3 siRNA, in contrast with the siHDAC3-treated group, the NF-kB p65 pathway activity was enhanced by LPS (P < 0.01), exposure to RGFP966 significantly inhibited LPS-enhanced NF-kB p65 pathway activation (P < 0.05). In contrast, we observed that pathway inhibition by Chr treatment was reversed after HDAC3 gene knockdown (Figure 6).
Next, immunofluorescence analysis was performed. NF-κB p65 nuclear localization signals were increased in the siHDAC3-LPS group, consistent with the expression of inflammation genes, HDAC3 knockdown almost entirely abrogated the inhibitory capacity of Chr-modulated NF-κB p65 nuclear translocation ( Figure 6F).
In brief, the Chr inhibitory effect on NF-κB p65 expression and on downstream proinflammatory gene expression was notably reversed in cells transfected with siRNA targeting HDAC3.

Chrysophanol Reduced
Lipopolysaccharide-Induced High Mobility Group Protein 1 Acetylation and Translocation Were Reversed After Knockdown of Histone Deacetylase 3 Expression by Small Interfering RNA As a part of the HDAC protein family, HDAC3 has been reported to play a key role in blocking HMGB1 secretion (Bonaldi et al., 2003). To further investigate the influence of Chr on HDAC3 activity and levels of acetylated HMGB1 and cytoplasmic to nuclear translocation, we transfected HDAC3 siRNA and NC-siRNA into RAW264.7; in addition, the HMGB1 inhibitor SB was used as a positive control. The distribution of HMGB1 was analyzed to determine the nucleocytoplasmic localization using fluorescence signals, HMGB1production was analyzed through ELISA, and IP was used to detect the HMGB1 acetylation level. As shown in Figures 7A,B, LPS induced translocation of HMGB1 protein from the nucleus to the cytoplasm; meanwhile, the inhibitory effects on HMGB1 translocation by Chr treatment were reversed in HDAC3 siRNA-transfected cells. In addition, ELISA results showed that HDAC3 siRNA eliminated the inhibitory effects of Chr on HMGB1 production in the cell culture supernatants (Figure 7C).
Immunofluorescent staining for HMGB1 recapitulated the results of WB and ELISA. In the HDAC3 siRNA control group and siRNA NC group, HMGB1 staining was only positive in the nucleus, whereas HMGB1 fluorescence signals were present in both the nuclear and cytoplasmic compartments in both the LPSand the Chr-treated groups ( Figure 7D). As shown in Figure 7E, after siRNA transfection, Chr treatment did not reduce LPSinduced HMGB1 acetylation. Collectively, these results demonstrated that Chr reversed LPS-triggered HMGB1 acetylation and nucleocytoplasmic translocation by enhancing HDAC3 expression.
Frontiers in Bioengineering and Biotechnology | www.frontiersin.org enhanced through treatment with 15 µM Chr ( Figure 7A). Moreover, similar results were observed when the cell extract was immunoprecipitated with the HDAC3 or NF-κB p65 antibody and followed by immunoblotting with HMGB1, NF-κB p65, or HDAC3, HMGB1 antibodies (Figures 8B,C).
Results verifying the relationship of the three proteins indicated that LPS induced HMGB1, NF-κB p65, and HDAC3 complex dissociation, whereas Chr enhanced the interaction between HMGB1, NF-κB p65, and HDAC3, which changes reflected our intended meaning.
Histone Deacetylase 3 Knockdown Suppressed Chrysophanol-Mediated Enhancement of HDAC3:HMGB1:NF-κB p65 Complex Formation Then, we used siRNA to knockdown HDAC3 expression in vitro. HDAC3 was decreased after transfection into RAW264.7 cells with siRNA for 48 h. Co-immunoprecipitation assays were carried out to test the interaction between the HDAC3:HMGB1:NF-κB p65 protein complex after HDAC3 knockdown by HMGB1 and NF-κB p65 antibodies, respectively. We found that under the NC or HDAC3-siRNA conditions, HMGB1 protein was detected in the IP product using the p65 antibody, and conversely, p65 protein was detected in the IP product using the HMGB1 antibody (Figures 9A,B). After LPS stimulation, the coexisting protein-protein interactions between HMGB1 and p65 were inhibited, which was observed in the siHDAC3-LPS group. Moreover, we observed from the IP product that HDAC3 knockdown potently abolished the Chraugmented p65:HMGB1 proteins complex formation, indicating the regulation role of HDAC3 in Chr-mediated enhancement of HDAC3:HMGB1:NF-κB p65 complex formation.

DISCUSSION
Sepsis is a life-threatening pathological condition characterized by a dysregulated inflammatory response, a disordered blood coagulation cascade, and multiple organ dysfunctions (Falagas and Kopterides, 2006;Jean-Baptiste, 2007;Prescott et al., 2016). The effective treatment of sepsis involves the inhibition of the expression of proinflammatory mediators. In our study, we examined the underlying mechanisms and protective effects of Chr in LPS-induced ALI in in vitro cell lines and in an in vitro LPS-induced murine model of ALI. Our findings explicitly demonstrated that Chr could significantly downregulate the HMGB1/NF-κB axis and inhibit the inflammatory response via modulation of HDAC3 expression. Finally, Chr treatment FIGURE 8 | Chr enhances interaction between HDAC3, HMGB1, and NF-κB p65. Immunoprecipitation of total and (A) anti-HMGB1-, (B) anti-HDAC3-, or (C) anti-NF-κB p65-antibody-treated lysates, respectively, subjected to WB.
FIGURE 9 | (A) Co-immunoprecipitation was performed using protein lysate from cells to observe relationship between HMGB1/NF-κB p65 complex formation in HDAC3 knockdown condition with specific siRNA and after LPS activation and Chr treatment. (B) Co-immunoprecipitation was performed to determine the interactions between p65-HMGB1. markedly enhanced protein-protein interactions and relieving symptoms of ALI.
The overproduction of inflammatory mediators has been associated with the pathogenesis of ALI; thus, the identification of effective measures to control lung injury is important. The therapeutic activity of DEX is attributed to its anti-inflammatory (Tolaj et al., 2017), immunosuppressive (Wang et al., 2013), antiendotoxic , and anti-shock (Yang et al., 2010) activity. Recent studies have determined that DEX possesses the capacity to activate the remission of organ injury and to overcome the infection, although the limitation of DEX treatment is that it is not recommended for long-term use, as it causes numerous adverse effects (Wang et al., 2013;Sun et al., 2017). Thus, there is an urgent need to identify novel effective treatments for ALI having fewer secondary adverse effects.
LPS induces the same disease characteristics as ALI and thus has been applied as the best model for ALI. We studied the protective effects of Chr in the ALI mouse model. The results showed that Chr sharply reduced MAP, the lung W/D weight ratio, lung MPO activity, MDA content in LPS-stimulated mice, FIGURE 10 | Schematic diagram of Chrysophanol-mediated suppression of the inflammatory response. and the levels of several inflammatory mediators in the BALF. In addition, Chr also increased SOD levels and the survival rate and, thus, effectively relieved ALI.
The level of lysosomal-specific MPO is an indicator of the active condition of macrophages (Yang et al., 2016), which contribute to inducing the oxidative stress reaction and causing organ or tissue damage (Jiang et al., 2016). Researchers have determined that the lipid peroxidation reaction induced by MDA (Diao et al., 2016) can lead to substantial cytotoxicity. SOD has been reported to be the major enzymatic antioxidative enzyme able to detoxify and eliminate free radicals . Our study suggested that Chr treatment could enhance SOD levels in contrast to the changes observed in the LPS group.
We then performed WB and ELISA to identify mechanisms involved in Chr protection against LPS-induced ALI. ALI is well known to develop from the increased exposure to cytokines released during the inflammation process. Our results indicated that the activation of LPS led to a significant increase in the activation of the NF-κB p65 pathway, as detected in the BALF, whereas Chr treatment disrupted the LPS-induced proinflammatory effects. Bacterial LPS triggering activation of the NF-κB signaling pathway has been considered to be a major component of ALI. LPS interacts with TLRs. In addition, as a late-onset risk factor, released HMGB1 induces the inflammatory cascade and accelerates the synthesis of inflammatory cytokines by binding to NF-κB receptors, which triggers NF-κB kinase phosphorylation, and signals that converge on the IkB/NF-kB, allowing the disruption of the complex, and shifting of NF-κB to the nucleus, leading to the release of large quantities of lethal factors (Jiang et al., 2005). Moreover, the results suggested that Chr treatment decreased LPS-enhanced expression of HDAC3, which is considered a transcriptional co-repressor of NF-κB p65. The HDAC3 inhibitor effectively inhibited NF-κB p65 transcriptional activity, likely by binding to the co-repressor transcription complex PPARγ (Jennewein et al., 2008).
In line with our in vivo study, we assumed that Chr could also inhibit activated cells and intrapulmonary lethal cytokines and relieve ALI through the HMGB1/NF-κB pathway via the HDAC3 signaling. The in vitro study was designed to define better the underlying molecular mechanisms involving Chr activity on the HMGB1/NF-κB signaling pathway. First, we found that Chr suppressed LPS-induced HMGB1 acetylation, which was in line with the reduction in HMGB1 nuclear translocation and extracellular HMGB1 production, suggesting a mechanism in which HDAC3 deacetylates HMGB1 and leads to the inhibition of HMGB1 release. Our previous study confirmed that Chr treatment inhibited the NF-κB p65 signaling pathway via inhibition of sIκB phosphorylation and NF-κB p65 relocation triggered by LPS-activated RAW264.7 cells (Wen et al., 2018). To provide a more in-depth exploration of how and whether Chr-regulated HMGB1 suppression influenced the HDAC3mediated inactivation of NF-kB p65, we used synthetic siRNA targeting HDAC3. We found that the inhibitory effect of Chr was essentially lost in cells where the expression of HDAC3 was silenced, suggesting an important role for HDAC3 in the effects induced by Chr.
Next, we explored the mechanisms involved in Chr-regulation of the p65:HDAC3:HMGB1 complex. Co-immunoprecipitation findings indicated that the members of the p65:HDAC3:HMGB1 complex were tightly bound to each other in the quiescent state. Then, we confirmed that after LPS activation, the binding between the components of the complex was disrupted, which might be a consequence of protein degradation. Furthermore, we showed that Chr treatment before LPS stimulation led to the stronger interaction between the complex components. When HDAC3 was knocked down, the enhancement effect of Chr was sharply abolished, suggesting an essential role of HDAC3 in the effects of Chr (Figure 10). In brief, our research showed that Chr possesses an intense anti-inflammatory effect by regulating HMGB1/NF-κB signaling through HDAC3.
Our study has some limitations. In our experiments, the potential mechanism of Chr via macrophages in vivo was not investigated. Thus, to better understand and characterize LPS-induced ALI, influence functions of other cell types (e.g., pulmonary macrophages and epithelial cells) are required to assess the clinical benefits of Chr further.

CONCLUSION
In conclusion, the present study showed that Chr exerts an intense anti-inflammatory effect by regulating HMGB1/NF-κB signaling through HDAC3 expression.

DATA AVAILABILITY STATEMENT
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/ Supplementary Material.

ETHICS STATEMENT
The animal study was reviewed and approved by the Animal Ethics Committee of Guangzhou University of Chinese Medicine.

AUTHOR CONTRIBUTIONS
QW and NL conceived and designed the experiments. QW performed the experiments, analyzed the data, prepared manuscript, and wrote the manuscript. NL contributed to the reagents, materials, and analysis tools. All authors read and approved the manuscript.